Effects of low doses of irradiation on the T-cell-mediated cytotoxic response

Gerber, Mariette; Pioch, Y; Dubois, Jean‐Bernard; Serrou, B

doi:10.1016/s0769-2625(83)80158-5

Cited by 6 publications

(3 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several studies have demonstrated the immunosuppressive effect of RT (particularly on T lymphocytes, which are considered the most radiosensitive cells of the hematopoietic system), from old preclinical models to more recent clinical studies (32)(33)(34)(35). Lymphocyte count has been demonstrated to decrease after administration of low-doses of pRT in patients with lung cancer (35).…”

Section: Discussionmentioning

confidence: 99%

Palliative radiotherapy in advanced cancer patients treated with immune‑checkpoint inhibitors: The PRACTICE study

et al. 2019

View full text Add to dashboard Cite

In the present study, the influence of purely palliative radiotherapy (pRT) on the outcomes of patients with advanced cancer undergoing immune checkpoint blockade was evaluated. Patients were stratified into three groups: Patients who had received pRT within 6 months prior to the initiation of immunotherapy (previous pRT); patients who received pRT during immunotherapy (concurrent pRT); and patients who did not receive RT prior to or during immunotherapy (no RT group), and these groups were compared. The median overall survival (mOS), median progression free survival (mPFS) and median time-to-treatment failure (mTTF) for the previous pRT group were significantly shorter compared with the no RT group (mOS, 3.6 vs. 12.1 months, respectively, P=0.0095; mPFS 1.8 vs. 5.4 months, respectively, P=0.0016; mTTF 1.8 vs. 5.7 months, respectively, P=0.0035). The concurrent pRT group had a longer mTTF compared with the previous pRT group and similar outcomes to the no RT group. In the previous pRT group, 26.9% of the patients experienced immune-related adverse events compared with 40.1% of patients in the no RT group. Despite the use of pRT during immunotherapy being considered safe, the results of the present study suggest that pRT has a negative effect on immune balance.

show abstract

Section: Discussionmentioning

confidence: 99%

Palliative radiotherapy in advanced cancer patients treated with immune‑checkpoint inhibitors: The PRACTICE study

et al. 2019

View full text Add to dashboard Cite

show abstract

“…In any case, the cell-killing effect is not observed following 10 cGy of TBI alone, as mentioned earlier, indicating that the enhancing effect caused by TBI may be due to some change in the host's radiosensitivities. Gerber et al reported that an exposure dose of 15 cGy or more to the spleen of tumor-bearing mice brought about a decrease in the activity of killer T cells, but in a dose range between 5 and 12 cGy the activity of killer T cells was increased (Gerber et al, 1981a, Gerber et al, 1981. These results suggest that opposite effects are caused by small differences in dose to the spleen.…”

Section: Discussionmentioning

confidence: 99%

Radiobiological Basis for Cancer Therapy by Total or Half-Body Irradiation

Sakamoto¹

2004

Nonlinearity in Biology, Toxicology, Medicine

View full text Add to dashboard Cite

show abstract

“…Several studies have since investigated the relationship between lowdose irradiation and the immune response (Gerber et al 1983;Liu et al 1987;Ibuki and Goto 1994). The results obtained from animal experiments demonstrated that low-dose whole-body irradiation enhanced the immune response by augmenting the proliferative reactive response of T cells to mitogenic stimulation (Kojima et al 2000a;Pandey et al 2005), altering cytokine release (Liu et al 2003;Cheda et al 2008) and immune cell populations (Ina and Sakai 2005), and/or augmenting T cell activation capacity by dendritic cells (Shigematsu et al 2007).…”

Section: Introductionmentioning

confidence: 99%

Effects of Low-Dose-Gamma Rays on the Immune System of Different Animal Models of Disease

Shimura

Kojima

2014

Dose-Response

View full text Add to dashboard Cite

ᮀ We reviewed the beneficial or harmful effects of low-dose ionizing radiation on several diseases based on a search of the literature. The attenuation of autoimmune manifestations in animal disease models irradiated with low-dose γ-rays was previously reported by several research groups, whereas the exacerbation of allergic manifestations was described by others. Based on a detailed examination of the literature, we divided animal disease models into two groups: one group consisting of collagen-induced arthritis (CIA), experimental encephalomyelitis (EAE), and systemic lupus erythematosus, the pathologies of which were attenuated by low-dose irradiation, and another group consisting of atopic dermatitis, asthma, and Hashimoto's thyroiditis, the pathologies of which were exacerbated by low-dose irradiation. The same biological indicators, such as cytokine levels and Tcell subpopulations, were examined in these studies. Low-dose irradiation reduced interferon (IFN)-gamma (γ) and interleukin (IL)-6 levels and increased IL-5 levels and the percentage of CD4Treg cells in almost all immunological disease cases examined. Variations in these biological indicators were attributed to the attenuation or exacerbation of the disease's manifestation. We concluded that autoimmune diseases caused by autoantibodies were attenuated by low-dose irradiation, whereas diseases caused by antibodies against external antigens, such as atopic dermatitis, were exacerbated.

show abstract

Effects of low doses of irradiation on the T-cell-mediated cytotoxic response

Cited by 6 publications

References 12 publications

Palliative radiotherapy in advanced cancer patients treated with immune‑checkpoint inhibitors: The PRACTICE study

Palliative radiotherapy in advanced cancer patients treated with immune‑checkpoint inhibitors: The PRACTICE study

Radiobiological Basis for Cancer Therapy by Total or Half-Body Irradiation

Effects of Low-Dose-Gamma Rays on the Immune System of Different Animal Models of Disease

Contact Info

Product

Resources

About